Abstract
To compare the efficacy and safety of adalimumab versus infliximab in an open-label prospective, comparative, multicenter cohort study of childhood noninfectious chronic uveitis. Thirty-three patients (22 females, 11 males, median age 9.17 years) with refractory, vision-threatening, noninfectious active uveitis were enrolled, and received for at least 1 year infliximab (5 mg/kg at weeks 0, 2, and 6, and then every 6-8 weeks) or adalimumab (24 mg/m2 every 2 weeks). The primary outcome was to assess, once remission was achieved, the time of a first relapse. Time to remission, time to steroid discontinuation, and the number of relapses were also considered. Sixteen children (12 with juvenile idiopathic arthritis [JIA], 3 with idiopathic uveitis, and 1 with Behçet's disease) were recruited in the adalimumab cohort and 17 children (10 with JIA, 5 with idiopathic uveitis, 1 with early-onset sarcoidosis, and 1 with Behçet's disease) were recruited in the infliximab group. Cox regression analysis did not show statistically significant differences between the two groups with regard to time to achieve remission and time to steroid discontinuation, whereas a higher probability of uveitis remission on adalimumab during the time of treatment was shown (Mantel-Cox χ2=6.83, P
| Original language | English |
|---|---|
| Pages (from-to) | 612-618 |
| Number of pages | 7 |
| Journal | Arthritis Care and Research |
| Volume | 63 |
| Issue number | 4 |
| Publication status | Published - Apr 2011 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Prevention of flare recurrences in childhood-refractory chronic uveitis : an open-label comparative study of adalimumab versus infliximab. / Simonini, Gabriele; Taddio, Andrea; Cattalini, Marco; Caputo, Roberto; De Libero, Cinzia; Naviglio, Samuele; Bresci, Cecilia; Lorusso, Monica; Lepore, Loredana; Cimaz, Rolando.
In: Arthritis Care and Research, Vol. 63, No. 4, 04.2011, p. 612-618.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevention of flare recurrences in childhood-refractory chronic uveitis
T2 - an open-label comparative study of adalimumab versus infliximab.
AU - Simonini, Gabriele
AU - Taddio, Andrea
AU - Cattalini, Marco
AU - Caputo, Roberto
AU - De Libero, Cinzia
AU - Naviglio, Samuele
AU - Bresci, Cecilia
AU - Lorusso, Monica
AU - Lepore, Loredana
AU - Cimaz, Rolando
PY - 2011/4
Y1 - 2011/4
N2 - To compare the efficacy and safety of adalimumab versus infliximab in an open-label prospective, comparative, multicenter cohort study of childhood noninfectious chronic uveitis. Thirty-three patients (22 females, 11 males, median age 9.17 years) with refractory, vision-threatening, noninfectious active uveitis were enrolled, and received for at least 1 year infliximab (5 mg/kg at weeks 0, 2, and 6, and then every 6-8 weeks) or adalimumab (24 mg/m2 every 2 weeks). The primary outcome was to assess, once remission was achieved, the time of a first relapse. Time to remission, time to steroid discontinuation, and the number of relapses were also considered. Sixteen children (12 with juvenile idiopathic arthritis [JIA], 3 with idiopathic uveitis, and 1 with Behçet's disease) were recruited in the adalimumab cohort and 17 children (10 with JIA, 5 with idiopathic uveitis, 1 with early-onset sarcoidosis, and 1 with Behçet's disease) were recruited in the infliximab group. Cox regression analysis did not show statistically significant differences between the two groups with regard to time to achieve remission and time to steroid discontinuation, whereas a higher probability of uveitis remission on adalimumab during the time of treatment was shown (Mantel-Cox χ2=6.83, P
AB - To compare the efficacy and safety of adalimumab versus infliximab in an open-label prospective, comparative, multicenter cohort study of childhood noninfectious chronic uveitis. Thirty-three patients (22 females, 11 males, median age 9.17 years) with refractory, vision-threatening, noninfectious active uveitis were enrolled, and received for at least 1 year infliximab (5 mg/kg at weeks 0, 2, and 6, and then every 6-8 weeks) or adalimumab (24 mg/m2 every 2 weeks). The primary outcome was to assess, once remission was achieved, the time of a first relapse. Time to remission, time to steroid discontinuation, and the number of relapses were also considered. Sixteen children (12 with juvenile idiopathic arthritis [JIA], 3 with idiopathic uveitis, and 1 with Behçet's disease) were recruited in the adalimumab cohort and 17 children (10 with JIA, 5 with idiopathic uveitis, 1 with early-onset sarcoidosis, and 1 with Behçet's disease) were recruited in the infliximab group. Cox regression analysis did not show statistically significant differences between the two groups with regard to time to achieve remission and time to steroid discontinuation, whereas a higher probability of uveitis remission on adalimumab during the time of treatment was shown (Mantel-Cox χ2=6.83, P
UR - http://www.scopus.com/inward/record.url?scp=79957511363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957511363&partnerID=8YFLogxK
M3 - Article
C2 - 21452272
AN - SCOPUS:79957511363
VL - 63
SP - 612
EP - 618
JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association
JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association
SN - 0893-7524
IS - 4
ER -